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As the key defense molecules originally identified in Drosophila, Toll-like receptor (TLR) superfamily members play a fundamental
role in detecting invading pathogens or damage and initiating the innate immune system of mammalian cells. The skin, the largest
organ of the human body, protects the human body by providing a critical physical and immunological active multilayered barrier
against invading pathogens and environmental factors. At the first line of defense, the skin is constantly exposed to pathogen-
associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), and TLRs, expressed in a cell
type-specific manner by various skin cells, serve as key molecules to recognize PAMPs and DAMPs and to initiate downstream
innate immune host responses. While TLR-initiated inflammatory responses are necessary for pathogen clearance and tissue
repair, aberrant activation of TLRs will exaggerate T cell-mediated autoimmune activation, leading to unwanted inflammation,
and the development of several skin diseases, including psoriasis, atopic dermatitis, systemic lupus erythematosus, diabetic foot
ulcers, fibrotic skin diseases, and skin cancers. Together, TLRs are at the interface between innate immunity and adaptive
immunity. In this review, we will describe current understanding of the role of TLRs in skin defense and in the pathogenesis of
psoriasis and atopic dermatitis, and we will also discuss the development and therapeutic effect of TLR-targeted therapies.
1. Introduction
The skin, poised at the interface between the host body and
the environment, is constantly exposed to pathogens and
environmental insults and therefore has evolved to provide
rapid and specific immune responses to these stimuli. Precise
and situation-specific innate immune responses of skin cells
to insults lead to rapid induction of host defense molecules
including antimicrobial peptides (AMPs) and proinflamma-
tory cytokines that shapes the adaptive immune responses,
leading to immediate as well as long-term protection against
pathogens or physical dangers.
Pattern recognition receptors (PRRs) are the vast array of
germline-encoded surveillance receptors responsible for rec-
ognizing pathogens, activating the innate immune system,
and priming antigen-specific adaptive immunity [1]. Upon
infection or injury, pathogen-associated molecular patterns
(PAMPs) released by a pathogen or damage-associated
molecular patterns (DAMPs) by damaged cells are taken up
by affected cells to activate membrane and/or cytosolic
PRRs. PAMPs or DAMPs, such as pathogenic or host
nucleic acid (DNA or RNA), protein, lipid, or lipoprotein,
can be detected by unique PRR and initiate differential
downstream signaling cascades, leading to situation-specific
host immune responses after bacterial, viral, and parasitic
infection and skin injury [2, 3].
Mammals have several highly conserved and distinct
classes of PPRs including Toll-like receptors (TLRs), RIG-I-
like receptors (RLRs), Nod-like receptors (NLRs), AIM2-
like receptors (ALRs), C-type lectin, and intracellular DNA
sensors such as cGAS-STING. Among different classes of
PRRs, TLRs were the first to be characterized and are the
most extensively studied innate immune receptors in both
vertebrates and invertebrates [4]. Mammalian TLRs were
first identified based on their sequence homology with the
Drosophila Toll gene, which was originally discovered by
Dr. Jules Hoffmann as the crucial receptor detecting micro-
organisms and activating the fly’s innate immune defense
response against bacterial infection [5, 6]. The discovery of
Toll-mediated innate immunity in Drosophila soon led to
the discovery of mammalian TLRs by providing evidence
that resistance to infection is mediated by inducible antimi-
crobial genes secondary to activation of the TLR signaling
pathway. Dr. Hoffmann was therefore awarded one half of
the 2011 Nobel Prize in Physiology or Medicine to acknowl-
edge his contribution to innate immunity.
The unique multilayered structure of the skin enables
an effective barrier against a relentless barrage of patho-
gens and insults. Anatomically, the skin comprises three
consecutive layers, including the stratified epidermis, the
fibroblast-rich dermis, and the dermal fat (also known as
dermal white adipose tissue (dWAT)) [7–9]. Keratinocytes
(KCs) are the main epidermal cell type (~95%), and the
remaining epidermal cells include Langerhans cells, mela-
nocytes, Merkel cells, and infiltrated immune cells. Dermal
fibroblasts (dFBs), the major resident cell types in the der-
mis, are highly heterogeneous [9, 10]. While dFBs located
in the upper (papilla) dermis support epidermal growth
and regulate hair cycling, dFBs located in the lower (retic-
ular) dermis have the potential to commit to preadipocytes
(pAd) and differentiate to adipocytes, forming the last and
deepest barrier of the skin, dWAT [9, 10]. PRR-mediated
innate immune activation of these skin resident cells by
PAMPs or DAMPs leads to the production of antimicro-
bial peptides as well as proinflammatory cytokines that
recruit and activate myeloid and lymphatic immune cells,
such as neutrophils, monocytes, dendritic cells, macro-
phages, and T lymphocytes. A proper interplay between
innate and adaptive immune cells confers immediate and
long-term immune protection against pathogens and insults.
While PRR activation is essential for inflammatory
responses that initiate skin’s host defense against invasive
pathogens, overactivation of PRRs often leads to uncon-
trolled inflammation and the subsequent development of
autoimmunity and/or inflammatory skin diseases, such as
psoriasis, atopic dermatitis, systemic lupus erythematosus,
and diabetes-induced impaired wound healing [11–13].
Here, we will review current literatures on the role of TLRs
in host defense and how aberrant activation of TLRs leads
to the development of psoriasis and atopic dermatitis and
recent advances in therapeutic targeting of TLR to treat these
skin diseases.
2. TLR Signaling
2.1. The Structure of TLRs and Their Cognate Ligands. TLRs
are type I transmembrane proteins consisting of three
domains including an extracellular domain, a single trans-
membrane domain, and an intracellular tail [14]. The extra-
cellular domain (ectodomains) contains tandem copies of
leucine-rich repeats (LRR) that recognize specific PAMPs
or DAMPs as a homo- or heterodimer along with a core-
ceptor molecule. The intracellular tail of TLRs is homolo-
gous to that of IL1 receptor, called the Toll/IL1R domain
(TIR), and it is required for downstream signaling trans-
duction. Upon PAMP or DAMP recognition, the TIR
domain recruits adaptor proteins, such as MyD88 (myeloid
differentiation primary response gene 88) or TRIF (TIR
domain-containing adaptor inducing IFNβ), which initiate
signaling cascades that activate NFκB (nuclear factor
kappa-light-chain-enhancer of activated B cells), MAPKs,
or TBK1 (TANK-binding kinase 1) signaling cascades to
regulate the expression of cytokines, chemokines, and anti-
microbial peptides that ultimately provide host defense
against danger signals [15, 16].
To date, 13 mammalian TLRs have been identified and
characterized, namely, TLR1 to TLR13, including TLR1-
TLR11 in human. Each TLR can interact with specific
PAMPs or DAMPs including lipopeptides for TLR1, TLR2,
and TLR6, lipopolysaccharide for TLR4, bacterial flagellin
for TLR5, dsRNA for TLR3, ssRNA for TLR7 and TLR8,
and DNA for TLR9 to initiate various intracellular signaling
events triggering innate immune responses (Figure 1). TLRs
(TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) are localized
at the cell plasma membrane to sense various cell wall com-
ponents from gram-positive bacteria or mycoplasma, or pro-
tein derivatives from damaged host cells. TLR4, together with
its extracellular partner CD14, recognizes lipopolysaccharide
(LPS), a cell wall component of gram-negative bacteria. TLR5
recognizes flagellins from either gram-positive or gram-
negative bacteria. TLR2 and/or TLR4 can also be activated
by endogenous ligands or DAMPs, such as biglycans, hya-
luronic acid, heat shock proteins, oxidized lipid, or lipopro-
teins [17, 18]. In contrast, TLR3, TLR7, TLR8, and TLR9
are localized in the endosome to detect nucleic acids derived
from viruses, bacteria, or damaged cells [19]. TLR3 recog-
nizes viral double-stranded RNA (dsRNA), TLR7 and TLR8
recognize single-stranded RNA (ssRNA) found during viral
replication, and TLR9 detects unmethylated deoxycytidyl-
phosphate-deoxyguanosine (CpG) DNA motifs commonly
found in bacterial and viral genomes. Studies have shown
that guanosine is also a TLR7 agonist, and binding of guano-
sine and ssRNA to two distinct sites on TLR7 leads to syner-
gistic activation of TLR7 [20, 21]. Under homeostatic
conditions, endogenous nucleic acids are usually not recog-
nized by these endosomal TLRs, but increasing evidences
have shown that TLR activation by endogenous RNA or
DNA is often associated with the development of autoimmu-
nity and inflammatory diseases [22]. The ligands for TLR10
or TLR11 remain unclear. Evidences have suggested that
TLR10 can form a heterodimer with TLR1, TLR2, or TLR6.
TLR11 may also play an important role in host defense
against certain infection as mice lacking TLR11 were highly
susceptible to uropathogenic bacterial infection in the kid-
ney. However, TLR11 may not be functional in human due
to the presence of stop codons in the open reading frame of
human TLR11 DNA which may represent a form of genetic
polymorphism and may lead to failure of the translation of
a full-length TLR11 protein [15, 23].
2.2. Signaling Pathway of TLRs. Activation of TLR signaling
requires homodimerization or heterodimerization of TLRs
or with coreceptors, which form an “m”-shaped dimer sand-
wiching the ligand molecule structure to facilitate dimeriza-
tion of the intracellular TIR domains and to trigger a
downstream signaling cascade [24]. TLR2 is known to form
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Figure 1: MyD88-dependent and TRIF-dependent TLR signaling pathways. Ligand binding of TLRs by their respective ligands induces
dimerization of TLRs and initiates MyD88-dependent or TRIF-dependent signaling cascades. The presence of coreceptors, such as CD14
for TLR2, TLR3, TLR4, TLR7, and TLR9, CD36 for TLR2 and TLR6, and CD44 for TLR4, promotes ligand binding efficiency to TLRs.
MD2 is a receptor component associated with TLR4 and enables TLR4 to respond to LPS. Activation of TLR1-TLR2 by the lipopeptide
Pam3CSK, TLR2-TLR6 by the lipopeptide Malp2, TLR5 by flagellin, or TLR4 by LPS recruits MyD88 through the adaptor molecule
TIRAP. MyD88 then recruits and activates the IRAK complex, which in turn activates TRAF6, which serves as a platform to recruit and
activate TAK1 in cooperation with TAB1-3. Once activated, TAK1 activates the IKK-NFκB pathway and the MAPK- (including P38,
ERK1/2, and JNK) AP1 pathway. Activated NFκB or AP1 translocates to the nucleus, driving the transcription of genes encoding
proinflammatory cytokines, antimicrobial peptides, and costimulatory molecules. Activation of endosomal TLR7 by ssRNA or guanosine,
TLR8 by ssRNA, or TLR9 by CpG-DNA not only initiates the MyD88-TRAF6-dependent activation of AP1 and NFκB but also triggers
the IRAK-, TRAF6-, TRAF3-, and IKKα-dependent activation of IRF7, translocation of which induces the transcription of type1
interferon genes including IFNα and IFNβ. In contrast, activation of TLR3 by dsRNA initiates the TRIF-dependent pathway, whereas
TLR4 activation induces both MyD88- and TRIF-dependent pathways. Once recruited to the intracellular domain of TLRs by TRAM,
TRIF initiates a TRAF3-dependent activation of the TBK1-type 1 IFN pathway and/or a TRAF6-dependent activation of the TAK1-
proinflammatory cytokine pathway. The TRAF3-dependent activation of TBK1 and IKKε and TBK1-mediated activation of AKT result in
the coordinate activation of the transcription factor IRF3, which translocates to the nucleus and induces the transcription of type 1
interferon genes upon activation. Pam3CSK4: tripalmitoyl-S-glycero-Cys-(Lys)4; Malp2: macrophage-activating lipopeptide-2; LPS:
lipopolysaccharide; dsRNA: double-stranded RNA; ssRNA: single-stranded RNA; CpG: deoxycytidyl-phosphate-deoxyguanosine; MyD88:
myeloid differentiation primary response gene 88; TIRAP: TIR domain-containing adaptor protein; TRAM: TRIF-related adaptor
molecule; TRIF: TIR domain-containing adaptor inducing IFNβ; TRAF: TNFR-associated factor; IRAK: IL1R-associated kinase; TAK:
transforming growth factor beta-activated kinase 1; TAB: TAK1-binding protein; IKK: inhibitor of nuclear factor kappa-B kinase; NFκB:
nuclear factor kappa-light-chain-enhancer of activated B cells; IκB: inhibitor of NFκB; TBK1: TANK binding kinase 1; AMPs:
antimicrobial peptides.
3Journal of Immunology Research
heterodimers with TLR1 or TLR6 to recognize distinct pep-
tidoglycan (PGN) or lipopeptides from gram-positive bacte-
ria or mycoplasma. For example, TLR2-TLR1 recognize the
bacterial lipopeptide Pam3CSK4 (tripalmitoyl-S-glycero-
Cys-(Lys)4), whereas TLR2-TLR6 recognize bacterial PGN,
lipoteichoic acid (LTA), and diacylated lipopeptides such
as Malp2 (macrophage-activating lipopeptide-2) [25, 26]
(Figure 1). The presence of coreceptors can promote the
ligand binding efficiency for several TLRs, such as CD14
for TLR2, TLR4, TLR3, TLR7, and TLR9, CD36 for TLR2
and TLR6, and CD44 for TLR4 [15, 27]. MD2 is a receptor
component associated with TLR4 and enables TLR4 to
respond to LPS or lipid A [16].
As shown in Figure 1, following ligand-induced dimer-
ization of the ectodomains of TLRs, the intracellular TIR
domains of TLRs dimerize and recruit TIR domain-
containing adapter proteins, such as MyD88, TIRAP (TIR
domain-containing adaptor protein), TRIF, and TRAM
(TRIF-related adaptor molecule). Depending on the adapter
usage, TLR signaling is generally divided into the MyD88-
dependent and TRIF-dependent pathways. All TLRs, except
TLR3, use the MyD88-dependent pathway to initiate signal-
ing, and TLR4 uniquely utilizes both MyD88 and TRIF path-
ways. After TLR engagement, TIRAP mediates recruitment
of MyD88, which then forms a complex with IRAK (IL1R-
associated kinase) family kinases, including IRAK1, IRAK2,
IRAK4, and IRAK-M, to induce TRAF6 (TNFR-associated
factor 6) activation. TRAF6, as an E3 ubiquitin ligase, acti-
vates TAK1 (transforming growth factor beta-activated
kinase 1) through the cooperation with TAB1/2/3 (TAK1-
binding protein). Activated TAK1 then phosphorylates the
IKK complex (inhibitor of nuclear factor kappa-B kinase),
which promotes the degradation of IκB (inhibitor of NFκB),
and the dissociated NFκB then translocates to the nucleus for
the induction of targeted genes. On the other hand, TAK1
can activate MAPK (mitogen-activated protein kinase) fam-
ily kinases, including stress-activated protein kinase p38,
Jun N-terminal kinase JNK, and signal-regulated kinase
ERK1/2; activation of these MAPKs leads to the activation
of the heterodimer of ATF2 and c-Jun, called AP-1. AP-1
translocates to the nucleus where it coordinates with NFκB
to initiate transcription of various inflammatory cytokines,
chemokines, and costimulatory factors [15].
Activation of TLR3 by dsRNA or TLR4 by LPS mediates
type 1 interferon (IFN) production via the TRIF-dependent
pathway. TRIF is first recruited to the TIR domain of TLRs
by TRAM, and TRIF recruits TRAF6 and/or TRAF3. TRAF6
recruits RIP1 (receptor-interacting protein 1) kinase, which
activates TAK1 and the subsequent NFκB and MAPK path-
ways. In contrast, TRAF3 recruits TBK1 (TANK-binding
kinase 1) and IKKε (inhibitor of κB kinase ε), which in turn
lead to the phosphorylation and nuclear translocation of
IRF3, an important transcription factor regulating IFNβ pro-
duction [28]. Ligand binding of TLR3 also activates the AKT
in a TBK1-dependent manner, and AKT contributes to IRF3
phosphorylation by interacting with TBK1 [29, 30]. In con-
trast, IFNα production upon activation of TLR7/8 by ssRNA
or TLR9 by CpG-DNA in plasmacytoid dendritic cells
(pDCs) is mediated by the MyD88 pathway [31]. A signaling
cascade involving MyD88, IRAKs, TRAF6, and IRF7 leads to
the activation and nuclear translocation of NFκB and IRF7,
which mediate the transcription of IFNα in activated pDCs.
3. TLRs in Skin Inflammatory Diseases
TLR signaling plays an essential role in host defense against
danger signals by producing a diverse range of cytokines,
chemokines, antimicrobial peptides, and costimulatory fac-
tors, and it is also required for adaptive immunity activation
for long-term protection. However, aberrant activation of
TLRs may disturb the homeostatic balance of the immune
system and may trigger the development of systemic auto-
immune diseases. For example, type 1 interferons, which
are the key antiviral cytokines induced during viral infection,
are potential triggers of several autoimmune diseases such as
systemic lupus erythematosus (SLE), psoriasis, rheumatoid
arthritis, diabetesmellitus, Sjogren’s syndrome, dermatomyo-
sitis (DM), and systemic sclerosis [31]. In addition to psoriasis
and SLE, unbalanced activation ofTLRsmay lead to other skin
diseases, such as atopic dermatitis, impaired wound closure,
diabetic foot ulcers, and skin cancer. Progression of these
localized skin diseases may lead to systemic diseases, pos-
ing a serious threat to human health and life [12, 32].
3.1. Expression and Function of TLRs in Skin Cells. TLRs are
expressed by various skin cell types in a cell-specific manner
[11, 13]. Keratinocytes, localized at the surface of the skin, is
the major epidermal cell type and are the first responders to
external pathogens or injury. TLR2 and TLR3 are the most
studied TLRs in keratinocytes, whereas the expression levels
of other TLRs, such as TLR4, TLR7, TLR8, and TLR9, are
much higher in myeloid immune cells compared to keratino-
cytes [22, 33–39]. Bacterial lipopeptide-mediated TLR2 acti-
vation in keratinocytes not only triggers the production of
proinflammatory cytokines such as TNFα and IL6 but also
enhances the tight junction barrier function of the epidermis
upon pathogen invasion [37, 39]. In contrast, dsRNA-
mediated TLR3 activation is required for normal inflamma-
tory response during viral infection, skin injury, or UV irra-
diation [33–35]. TLR3 is also required for normal skin
barrier repair following tissue damage, and activation of
TLR3 induces the expression and function of tight junction
components and markedly enhances reepithelialization,
granulation, and neovascularization required for wound
healing [36, 40].
While the innate immune function of keratinocytes has
been extensively studied, the immune functions of dFBs
and adipocytes in host defense and tissue repair have only
been unrevealed and recognized recently [9, 22, 41, 42]. dFBs
express functional TLR2 and TLR4 [43, 44]. TLR2-mediated
recognition of bacterial lipopeptides or fungal pathogen Can-
dida albicans and TLR4-mediated recognition of LPS stimu-
late the production of proinflammatory cytokines such as IL6
to promote both innate and adaptive immunity against path-
ogen invasion [43, 44]. However, excessive activation of
TLR2 or TLR4 in dFBs by endogenous DAMPs such as
TLR4 ligands hyaluronan, fibrinogen, and other ECM pro-
teins or TLR2 ligand serum amyloid A (SAA) may lead to
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the pathogenesis of fibrotic skin disorders, such as hyper-
trophic scarring and systemic sclerosis (SSc) [43–45]. dFBs
have the potential to commit to preadipocytes (pAds)
which can differentiate into adipocytes upon stimulation.
Our group has shown that dermal infection with the
gram-positive bacteria Staphylococcus aureus (S. aureus)
triggers a dermal reactive adipogenesis response, character-
ized by dFB commitment to pAd in response to infection,
and then pAd proliferation followed by adipocyte differen-
tiation, and during this process, the antimicrobial peptide
cathelicidin (CAMP) is abundantly secreted by differentiat-
ing adipocytes, conferring host resistance to the invasive S.
aureus infection [9, 41, 42]. In vitro, S. aureus or TLR2
ligand treatments enhance the adipogenic potential of pri-
mary mouse dFBs [42], suggesting that TLR2 activation
may drive the commitment of dFB to adipocyte lineage
and enable dFB’s ability to produce antimicrobial peptide
during the subsequent differentiation step. Together, with
emerging roles for dFBs in host defense being unrevealed,
studies are urgently needed to define the role of TLRs in
activating dFBs.
Dendritic cells (DCs), known as the professional antigen-
presenting cells (APCs), function as immune sentinels and
play a pivotal role in bridging innate and adaptive immunity
in the skin [46]. DCs uptake and process antigens and
become functional mature antigen-presenting cells followed
by migration to lymph nodes, where they prime T cell differ-
entiation and activation to induce adaptive immune
responses to microbials, vaccines, and self-antigens. TLRs
are critical molecules for antigen presentation and induction
of cytokines, chemokines, and costimulated molecules in
DCs. Langerhans cells (LCs), a unique subset of APCs located
in the epidermis between keratinocytes, rapidly sense
PAMPs, DAMPs, or antigens and migrate to lymph nodes
to prime T cells to elicit appropriate cutaneous immune
responses for host defense [47, 48]. TLR2 is the most prom-
inent TLR expressed in LCs, and LCs also express TLR8,
TLR4, and TLR3 [49]. Activation of TLR2 or TLR7/8 in
LCs leads to the production of proinflammatory cytokines
such as IL12, CCL3, and IL8, whereas TLR3 stimulation in
LCs induces the expression of chemokines (CXCL9,
CXCL11, and CXCL10) and IFNβ [47]. DCs in the dermis
can be subdivided into conventional DCs (cDCs) and plas-
macytoid DCs (pDCs) [50]. While cDCs normally reside in
the skin under homeostatic condition, pDCs are not present
in healthy skin but rapidly infiltrate the skin dermis upon
injury [50, 51]. We and others have shown that cDCs express
most TLR family genes at moderate levels whereas TLR7 and
TLR9 and their downstream signaling molecule IRF7 are
preferentially expressed at high levels in pDCs [22, 52]. This
unique TLR expression signature enables pDCs to rapidly
respond to ssRNA or DNA and produce high levels of type
1 IFNs, especially IFNα family genes, to promote autoim-
mune activation [22].
TLR-mediated innate immune activation of skin-resident
keratinocytes, fibroblasts, and dendritic cells promotes the
activation or recruitment of myeloid-derived immune cells
such as neutrophils and macrophages or adaptive immune
cells such as T cells, leading to immediate and long-term
immunity against danger signal. During wound healing, ces-
sation of the initial defensive/inflammatory phase is required
for the subsequent proliferative and remodeling phases to
complete the healing process and return to homeostatic con-
dition. Therefore, unresolved or excessive inflammation not
only can lead to the development of autoimmune skin dis-
eases such as psoriasis, atopic dermatitis, rosacea, lupus,
and systemic sclerosis but also can lead to defective or aber-
rant wound healing as seen in wound ulcers, diabetic foot
ulcers, keloid, or hypertrophic scars [12, 53, 54] (Figure 2).
We will next focus on reviewing the roles of TLRs in the
pathogenesis of the two most common inflammatory skin
diseases: psoriasis and atopic dermatitis.
3.2. Innate Immune Activation of TLRs and Psoriasis
Initiation. Psoriasis is a chronic, recurrent, genetic autoim-
mune skin disorder featured by well-demarcated, raised
areas of erythematous plaques, often covered by silvery
scaling [55]. It is estimated that ~1.7% of the world popu-
lation is affected by psoriasis, including ~3% of the US
and European populations and ~0.5% of the Chinese or
Asians [56]. Principal histological features of psoriasis are
hyperplastic epidermis, increased vascularity in the dermis,
and dermal infiltration with inflammatory leukocytes.
There is no cure for psoriasis, and the recurrence of psori-
asis can be triggered by several factors such as skin injury,
infection, stress, and drugs such as β blockers, lithium, type
1 interferons, and imiquimod [57].
Psoriasis is considered a T cell-mediated disease, because
T cell-derived cytokines such as IL17A and IL22 are respon-
sible for the hyperproliferation and aberrant differentiation
of keratinocytes that ultimately leads to psoriatic plaque for-
mation. However, PRR-mediated recognitions of DAMPs or
PAMPs and the resultant innate immune responses in kera-
tinocytes or pDCs are believed to be the early initiating events
in psoriasis that drive the subsequent adaptive immunity and
autoimmunity development. Upon DAMP or PAMP stimu-
lation, keratinocytes are capable of producing an array of
proinflammatory cytokines, such as IFNβ, IL1β, IL36, TNF,
IL6, IL8, IL25, and CXCL10, to initiate the inflammatory T
cell phenotype in psoriasis [22, 58–60].
Skin injury even superficial tattoos can trigger psoriasis,
and this is known as the “Koebner phenomenon.” We have
recently shown that PRR-mediated activation of the innate
immune responses in keratinocytes plays a role in triggering
psoriasis upon skin injury [22]. During skin injury, damaged
cells release DAMPs such as dsRNA, ssRNA, and DNA, and
we have found that the antimicrobial peptide LL37 which is
upregulated during wounding enables dsRNA recognition
in keratinocytes through the TLR3 andmitochondrial MAVS
(mitochondrial antiviral signaling protein) signaling path-
way, leading to IFNβ production from KC or pDC, respec-
tively [22, 61]. Dr. Gilliet’s group has also shown that LL37
can also enable ssRNA or DNA recognition by TLR7 or
TLR9 in pDCs, which then produce a large quantity of IFNα
[51, 61]. The self-ssRNA-LL37 complexes also activate cDC
through TLR8, leading to the production of TNFα and IL6
and cDC maturation [62]. Direct comparison of the tran-
script levels of PRRs in KC, pDC, and cDC reveals that while
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TLR3 is expressed at similar levels in all cells, MAVS is
preferentially in KCs, TLR4 and TLR8 are expressed at
higher levels in cDCs, and TLR7-TLR9 are preferentially
expressed by pDCs [22]. These cell type-specific expression
patterns of PRRs can explain the cell type-dependent
responsiveness to various DAMPs or PAMPs during skin
injury. Type 1 IFNs, including IFNβ from KCs and IFNα
from pDCs, serve as early cytokines released upon injury
to promote cDC activation and maturation with conse-
quent Th17 T cell development and the beginning of the
autoimmune self-amplification loop that drives pathogenic
hyperproliferation of KCs and manifestations of psoriasis.
The roles of TLR2 or TLR4 in psoriasis still remain
unclear. The expression of TLR2 and TLR4 on peripheral
blood mononuclear cells and keratinocytes is elevated in
patients with psoriasis [63, 64]. There is also an association
between polymorphisms within TLR4 with chronic plaque
type psoriasis and psoriatic arthritis [65]. A recent study
has shown that epidermal infiltration of neutrophils drives
inflammatory responses in the skin through activation of
the epidermal TLR4-IL36R crosstalk in the imiquimod-
(IMQ-) induced psoriasis-like mouse model [66]. Addition-
ally, heat shock proteins (HSPs), such as HSP27, HSP60,
HSP70, and HSP90, are overexpressed in KCs of psoriasis
patients, and these HSPs can function as autoantigens to
activate antigen-presenting cells (APC) through TLR4 to
promote APC maturation and secretion of TNFα and
IL12 [67–69].
In summary, psoriasis is a complicated autoimmune dis-
ease mediated by the dynamic interplay between the innate
and the adaptive immune cells. TLR-mediated activation of
keratinocytes, pDCs, and/or cDC initiates early innate
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Figure 2: Proposed model for the role of TLR-mediated innate immune events in regulating the Th1/Th17 and Th2 immune balance. The
development of Th1/Th17 T cells can be initiated upon innate immune activation of several TLRs, including TLR3 and MAVS
(mitochondrial antiviral signaling protein) in keratinocytes (KCs), TLR7 and TLR9 in pDCs, TLR8 in cDCs, TLR2 in KCs and monocytes
(Mon), and TLR4 in monocytes. Activation of these TLR-mediated signaling events leads to elevated expression of proinflammatory
cytokines, type 1 interferons (including IFNβ from KCs and IFNα from pDCs), antimicrobial peptides (AMP), and costimulatory
molecules (on cDCs and pDCs), which ultimately promote the differentiation of T cells from the Th0 to Th1/Th17 phenotype. In contrast,
impaired TLR2 may play a role in the development of Th2 immune response. Genetic factors (such as TLR2 polymorphisms) or lack of
early childhood exposure to microbes impairs TLR2 expression, and the resultant defective TLR2 signaling leads to decreased expression
of antimicrobial peptides (AMPs), compromised epithelial barrier integrity, and decreased expression of Th1/Th17 cytokines. Impaired
barrier integrity plays a central role in driving the allergic Th2 immune response by allowing allergens to penetrate through the skin
surface. In addition, lack of AMP expression in the skin epidermis promotes dysbiosis of the skin microbiome and overgrowth of S.
aureus, which releases several virulent toxins that exacerbate the disruption of barrier integrity and the expression of inflammatory Th2
cytokines. Activation of the Th1/Th17 immune system is necessary to promote autoimmunity and host defense against pathogens and
cancer cells, but overstimulation of the Th1/Th17 pathway drives the development of several autoimmune diseases, including psoriasis,
systemic lupus erythematosus (SLE), and fibrotic skin diseases (e.g., hypertrophic scarring and systemic sclerosis (SSc)). On the other
hand, activation of the Th2 immune system is necessary to elicit normal allergic immune responses to allergens or pathogens, but
overstimulation of Th2 immune response early in life initiates the progression of allergic diseases including atopic dermatitis, asthma, and
allergic rhinitis, a pathological process known as “atopic march.”
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immune events that link to T cell activation and the develop-
ment of autoimmunity in psoriasis. Current psoriasis thera-
pies targeting T cell activation are effective in clinical trials
[57], but potential problems including lack of long-term effi-
cacy and rapid relapse of the disease upon drug removal [70–
72] suggest that targeting the T cell alone is not enough. Tar-
geting PRR-mediated innate immune activation of KCs or
pDCs in the combination of T cell therapies may result in
more sustainable effect to treat psoriasis.
3.3. Dysbiosis of Skin Microbiome, Impaired TLR2 Function,
and Atopic Dermatitis. Atopic dermatitis (AD), a chronic,
inflammatory skin disease characterized by an eczema-like
lesion and intense pruritus and high serum immunoglobulin
E (IgE), is a major health problem worldwide affecting
15~20% of children and 2~3% of adults [73–76]. AD often
begins early in infancy around 3 months of age, and about
80% children have a spontaneous remission of the disease
before adolescence, whereas the remaining 20% continue to
have eczema into adulthood. Children with persistent AD
symptoms often develop asthma and/or allergic rhinitis from
3 years of age, a process known as “atopic march” [75, 77].
Studies suggest that environmental factors may be critical
in disease progression of AD. First, the prevalence of symp-
toms of AD is about 5~10 times higher in developed coun-
tries such as the United Kingdom, Japan, Australia, and the
USA compared to developing countries such as Iran and
China [75, 76]. Furthermore, the development of AD is
inversely associated with early childhood exposure to infec-
tions or microbe-rich environment such as living with older
siblings or pets or on a farm [78] (Figure 2). A hygiene
hypothesis has therefore been proposed to describe the pro-
tective influence of microbial exposure to early life on the
development of AD [78].
Recent studies have shown that dysbiosis of skin micro-
bial community (microbiome) may promote disease progres-
sion of AD (Figure 2). The lesional skin of AD patients is
often colonized with S. aureus, and skin S. aureus coloniza-
tion not only positively correlates with disease severity but
also precedes the clinical diagnosis of AD, suggesting that S.
aureus may actively contribute to AD pathogenesis [79–81].
High-throughput DNA sequencing of the bacterial 16S
rRNA has revealed that while bacterial composition is highly
diverse on healthy skin, there is a dramatic loss of skin micro-
bial diversity during AD flares, and the proportion of Staph-
ylococcus shifts from ~20% in normal skin to a dominant
~90% in AD flare [82]. The main consequence of increased
colonization of S. aureus in AD skin is the exacerbation of
the allergic Th2 inflammatory response by staphylococcal
enterotoxins (also known as “superantigens”) and phenol-
soluble modulins (PSMs) [83–85] and the disruption of epi-
dermal barrier integrity mediated by other virulence factors
of S. aureus (e.g., S. aureus proteases, such as aureolysin
and V8 protease) [86]. A recent study from the Gallo lab
has also shown that S. aureus-derived PSMα also induces
the expression of endogenous protease activity in keratino-
cytes, further contributing to the disruption of barrier
homeostasis [87]. Lack of early childhood exposure to bene-
ficial microbes likely promotes dysbiosis of the skin micro-
biome. Indeed, studies from the Gallo group have shown
that the commensal bacteria S. epidermidis can secrete anti-
microbial peptide or DNA analog to suppress the growth of
pathogenic bacteria S. aureus or group A Streptococcus
(GAS), and furthermore, the commensal bacteria S. hominis
can suppress toxin production from S. aureus through an
autoinducing peptide [87–89]. Together, these evidences sug-
gest that imbalanced skin microbiome composition and
overgrowth of S. aureus are key triggering factors for the
pathogenesis of atopic dermatitis.
Impaired TLR2 function has been associated with the
pathogenesis of atopic dermatitis (AD) (Figure 2). Genetic
polymorphisms of TLR2 have been identified to be associated
with AD [90, 91], and TLR2 was also found to be downregu-
lated in macrophages or peripheral blood mononuclear cells
(PBMC) isolated from peripheral blood from AD patients
[92–94]. Additionally, macrophages or PBMC from AD
patients treated with TLR2 ligands produce significantly less
TH1/TH17 cytokines such as interleukin 6 (IL6), IL1β, IFNγ,
IL12, and IL17F and IL22, but more TH2 cytokine IL5
[93, 95]. S. aureus-mediated TLR2 activation is also strongly
impaired in Langerhans cells from AD skin [48]. Confocal
microscopy of skin sections from normal or AD patients
revealed that TLR2 is normally expressed throughout the epi-
dermis but limited to the basal keratinocytes in AD skin [92].
In normal keratinocytes, activation of TLR2 rapidly increases
the expression of tight junction (TJ) protein claudin1 and
antimicrobial peptide (AMP) genes such as β-defensins and
cathelicidin in differentiated epidermal layers [96]. However,
the lesional skin of AD patients expresses significantly
decreased levels of TJ proteins as well as AMPs [96, 97], indi-
cating that TLR2 signaling is impaired in the suprabasal
layers of the epidermis where these genes are expressed.
Therefore, impaired TLR2 signaling in various skin cells
from AD patients may ultimately skew the immune response
to S. aureus toward a TH2-dominant immune phenotype, a
hallmark of allergic diseases such as AD. Cytokines produced
by TH2 lymphocytes including IL4, IL5, and IL13 are central
to the pathogenesis of atopic diseases [98].
While TLR2 signaling is impaired during the acute phase
of AD, it has also been suggested that aberrant activation of
TLR2 may play a role in promoting the development of the
Th1 immune pathway that leads to the exacerbation and
persistence of inflammation during the chronic phase of
AD [99, 100]. Thymic stromal lymphopoietin (TSLP), a cyto-
kine highly expressed by epidermal keratinocytes in AD skin,
has been recognized as the master regulator linking innate
response at the barrier surface to TH2-skewed adaptive
immune response in atopic diseases [101, 102]. The expres-
sion of TSLP can be triggered by exposure to environmental
factors, such as allergens and microorganisms, and elevated
TSLP expression is observed before the development of clin-
ical AD phenotypes in both human and mice [101, 103], sug-
gesting that TSLP is the early initiating factor driving AD
pathogenesis. In vitro, TLR ligands (including TLR3 ligand
poly (I:C), TLR2-6 ligand FSL1, and TLR5 ligand flagellin)
or isolated S. aureus membrane components induce TSLP
expression and release from primary human keratinocytes,
and TSLP expression can also be regulated by vitamin D3
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and TH2 cytokines (IL4 and IL13) in human KCs [104].
Considering that TSLP can be induced upon activation of
several TLRs (including TLR2 and TLR3) or by TLR-
independent mechanisms [101], it is still unclear whether
aberrant activation of TLR2 contributes to high TSLP expres-
sion in AD. Future studies are needed to define the role of
TLR2 in TSLP expression and in converting AD from a
Th2-dominant acute phase to a Th2-Th1 mixed chronic
inflammation phase.
4. TLR-Targeted Therapies
TLRs play important roles in linking innate and adaptive
immune responses to initiate immediate as well as long-term
host defense against danger signals, and dysregulations of
TLRsare responsible for thepathogenesis of several inflamma-
tory skin diseases, and therefore, targeting TLRs is of great
therapeutic potential to treat skin diseases. Several TLR ago-
nists or antagonists or TLR modulators have been approved
or are currently in development to treat skin diseases [105].
We will next review TLR’s therapeutic implication, recent
advances, and future prospects in treating skin diseases.
4.1. Therapeutic Use of TLR Ligands to Boost Host Immunity
against Pathogens or Cancer. TLR agonists have been used to
treat infectious skin diseases by boosting host innate
immune defense against pathogens. Candida albicans, a fun-
gal member of the normal human skin microbiome, is nor-
mally harmless, but in immunodeficient patients, it can
cause life-threatening infections. Amphotericin B (AmB), a
commonly used antifungal agent, stimulates several TLRs
(TLR1, TLR2, and TLR4) followed by the production of pro-
inflammatory cytokines such IL6, IL8, and TNF, boosting
the host’s immunity against C. albicans [106]. Caspofungin
(echinocandins), a new class of antifungal drugs, inhibits
the synthesis of β-glucan in the fungal cell wall by influenc-
ing the interactions between Dectin1 and TLR2, TLR4, or
TLR9 [107]. TLR ligands have also been used for the treat-
ment or vaccine development for herpes simplex virus
(HSV) [105]. In mice, HSV vaccines adjuvanted with the
TLR9 agonist unmethylated CpG are superior to the unadju-
vanted vaccine at eliciting a robust HSV-specific cell-
mediated immune response [108].
TLR agonists have also been used to boost locoregional
and systemic immunity against cancer. Imiquimod (IMQ),
a TLR7/8 ligand, is the first US FDA-approved drug to
treat external genital and perianal warts and then
approved for actinic keratosis and basal cell carcinoma
(BCC), the most common skin cancer worldwide [109].
The effect of IMQ is mediated by recruitment and activation
of pDC, cDC, or macrophages through TLR7/TLR8, leading
to the production of cytokines including type 1 IFNs, IL1,
IL6, and TNF followed by the development of cell-mediated
adaptive immunity against cancer cells [109]. Due to its
autoimmune-stimulatory capacity, a known side effect of
IMQ is the development of psoriasis-like skin inflammation
in both human and mice, and therefore, topical application
of IMQ has been commonly used as a method to trigger
psoriasis-like skin inflammation in mice. Synthetic unmethy-
lated CpG type B oligodeoxynucleotide CpG 7909, the TLR9
agonist that stimulates DC, macrophages, or NK cells, has
been shown to be effective against BCC and metastatic mela-
noma [110, 111]. Other TLR ligands, such as TLR3 ligand
poly (I:C), a synthetic analog of viral dsRNA, can be used
in combination with antitumor nanoparticles to promote
melanoma regression in mice by promoting melanocyte apo-
ptosis and shifting macrophages to a proinflammatory and
tumoricidal phenotype [112].
4.2. Therapeutic Effects of TLR Inhibition in Psoriasis.
While the TLR7-8 agonist imiquimod triggers psoriasis,
synthetic oligonucleotides, antagonists for TLR7-9, can
suppress Th1 and Th17 immune development in a mouse
model of IL23-induced psoriasis [113]. In addition, several
oligonucleotide-based antagonists of TLR7-9 such as IMO-
3100 and IMO-8400 have been shown to be safe and effec-
tive in phase 2 clinical trials in patients with moderate-to-
severe plaque psoriasis by blocking the activation of the
IL17 pathway [114].
Conventional psoriasis therapies, including topical
applications of vitamin D analogs or vitamin A analogs,
have also been shown to exert their anti-inflammatory
effects by modulating TLR function. Vitamin D3 downre-
gulates the expression of TLR2, TLR4, and TLR9 and sup-
presses TLR9-mediated cytokine production in human
monocytes [115], and the vitamin D analog calcipotriol
attenuates CpG-mediated elevation of TLR9 and MyD88
expression in pDCs [116]. Retinoids, namely, vitamin A
and its metabolites, have been used to treat psoriasis since
the 1980s. Retinoid-mediated activation of retinoic acid
receptors (RAR) and retinoid X receptors (RXR) improves
the symptoms of psoriasis by regulating cell proliferation/-
differentiation as well as by suppressing inflammation
[117]. Retinoid analog can reduce the expression of TLR2
and its coreceptor CD14 in human monocytes and there-
fore prevent TLR2-mediated innate immune response to
microbes [118, 119].
Together, inhibition of TLRs by specific TLR antagonists
or by natural compounds such as vitamin A or D analogs
attenuates the activation of the innate immune system that
initiates the autoimmune cascade in psoriasis. Although
new biological drugs targeting T cell activation molecules
such as TNFα (such as etanercept, adalimumab, and inflixi-
mab), IL12 and IL23 (such as ustekinumab), IL23 (such as
guselkumab, tildrakizumab, and risankizumab), IL17A (such
as secukinumab and ixekizumab), or IL17 receptor A (such
as brodalumab) have shown to be safe and efficacious in
recent psoriasis clinical trials, however, lack of long-term effi-
cacy and rapid regain of psoriasis upon removal of these
drugs suggest that preventing adaptive immune activation
alone is not sufficient to treat psoriasis. Targeting TLRs or
PRRs in combination with T cell therapy may result in more
sustainable effect to treat psoriasis.
4.3. TLRs and Atopic Dermatitis. As we have described
earlier, impaired TLR2 function plays a role in driving loss
of barrier integrity and the immune system imbalance
(Th2 dominance) during the acute phase of AD, but
8 Journal of Immunology Research
aberrant activation of TLR2 may lead to Th1 immune
development during the chronic phase of AD and may
also lead to the production of keratinocyte-specific cyto-
kine TSLP that drives the allergic immune responses.
Therefore, strategies that finely modulate TLR2 expression
or function hold promise in restoring barrier function and
immune balance in AD.
Topical calcineurin inhibitors (TCIs), including tacroli-
mus and pimecrolimus, are FDA-approved drugs for the
treatment of AD. TCIs block the activity of the enzyme cal-
cineurin, to prevent the activation of the nuclear factor of
activated T cells (NFAT), which in turn blocks cytokine IL2
production as well as the subsequent T cell activation and
proliferation [120–122]. It has also been reported that the
abnormal expression of TLR1 and TLR2 can be normalized
after a 3-week treatment with tacrolimus ointment [123],
suggesting that TCIs may exert their therapeutic effects by
restoring normal function of TLR2 signaling in AD.
5. Conclusion
Skin, located at the first line of defense, is constantly
exposed to pathogenic or danger factors from the environ-
ment. TLRs, the key pattern recognition receptors, are
involved in the recognition of PAMPs or DAMPs, initia-
tion of innate immune responses, regulation of adaptive
immune responses, and ultimately development of imme-
diate and long-term immunity against pathogens. There
is a growing body of evidence demonstrating that TLRs
play indispensable roles in the pathogenesis of several
inflammatory skin diseases, and therefore, therapeutic
strategies have been developed and studied to target TLRs
to either boost immunity against pathogens or cease aber-
rant activation of TLRs that drives autoimmune activation.
But with recent success in the new biological drugs target-
ing T cells, the effector cell type at the downstream of dis-
ease progression, therapeutic approaches targeting innate
immune activation during early stages of disease progres-
sion become less favorable. However, inhibiting the activa-
tion of the adaptive immune activation alone, without
blocking the early innate immune events, can only allevi-
ate disease symptoms but cannot cure the disease and
may lead to rapid regain of inflammation upon drug
removal. Future studies will be needed to develop targeted
therapies for TLRs or PRRs which may be used in combi-
nation with T cell-targeted therapy to achieve more sus-
tainable interventions to treat inflammatory skin diseases,
such as psoriasis or atopic dermatitis.
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